Pharma Trend
  • Pharma Trend
  • Pharma Award
    • Golden Tablet
    • Most innovative Product
    • Honorary Award
  • Pharma Ranking
  • Impressions
  • Sponsors & Partners
  • News
    • Gastroenterologists
    • Industry
    • Pain Therapists
    • Urologists

Daiichi Sankyo receives the “Most Innovative Product” award from oncologists for Enhertu® and is ranked 8th in the Pharma Trend Ranking 2022

October 7, 2022 by Editorial staff

Daiichi Sankyo is ranked 8th in the multidisciplinary “Best Pharmaceutical Companies Germany” 2022 ranking in the category “Large individual, medium-sized and international companies”. Infectopharm, Gedeon Richter, ALK-Abelló and Exeltis placed first this year. Daiichi Sankyo’s most recent new product launch and winner of the “Most Innovative Product” award from the oncologists is the breast cancer drug Enhertu®.

Among several new preparations for the treatment of advanced breast cancer, every third oncology specialist surveyed (33%) in the Pharma Trend Study 2022 chose Enhertu® as the most innovative product in 2022. In the spontaneous nominations without a specification, a further 8% chose Trodelvy® (Gilead Sciences), 7% Keytruda® (MSD) and 5% Tukysa® (Seagen). The decisive criteria for the preparations for the treatment of breast cancer for the oncologists were an innovative mode of action – 70% named this – an improved effect (58%), the novelty on the market (40%) as well as new combination possibilities (30%).

Daiichi Sankyo: innovator in cardiology and oncology

Daiichi Sankyo Co., Ltd. is a Japanese, globally active, research-based pharmaceutical company headquartered in Tokyo (Jap. Daiichi Sankyō Kabushiki kaisha). It resulted from the merger of the Sanky Co., Ltd. founded in 1899 and the Daiichi Pharmaceutical Co., Ltd. founded in 1915 and is one of the 20 largest pharmaceutical companies in the world. Around 16,500 employees generated a turnover of 1044.9 billion JPY (Japanese yen) in 2021, equivalent to approx. 7.52 billion euros.  The annual report states that expenditure on research and development amounted to 260.2 billion JPY, corresponding to approx. 1.87 billion euros, i.e. around 25% of sales – a comparatively high percentage even in the pharmaceutical industry.

Daiichi is present in 26 countries. Both the European headquarters, Daiichi Sankyo Europe GmbH, and the German subsidiary, Daiichi Sankyo Deutschland GmbH, are based in Munich.

Daiichi has made a strong name for itself in cardiology, starting with the first isolation of adrenaline in 1900 – the adrenal medullary hormone that became the first blockbuster drug of the 20th century. Sankyo researchers discovered the first HMG-CoA reductase inhibitor in 1973, the origin of statins to lower cholesterol. In 1989, the first AT-II receptor blocker was launched, the origin of blood pressure-lowering sartans. In 2015 came Edoxaban®, an anticoagulant tablet. The current portfolio also includes drugs for the treatment of atrial fibrillation (e.g. Lixiana®), hypertension (e.g. Olmetec®, Sevicar®), lipid metabolism disorders (e.g. Mevalotin®, Lopresor®, Lomir®, Nilemdo®) and thrombotic diseases (e.g. Efient®). Another well-known drug is Evista® for osteoporosis in postmenopausal women.

In addition to a strong portfolio of cardiovascular disease medicines, Daiichi Sankyo’s Vision 2025 focuses on becoming a “global pharmaceutical innovator with a competitive advantage in oncology”. To this end, the company aims to provide novel therapies in oncology in particular, as well as in other research areas that address rare diseases and immune disorders. An innovative oncology drug was already irinotecan in 1995.

A promising current innovation is trastuzumab-deruxtecan (T-DXd, Enhertu®), an anti-HER2-directed antibody-drug conjugate (ADC) in metastatic breast cancer that delivers a targeted cytotoxic agent to diseased cells. In 2022, it received second-line approval in the EU and the Oncologists’ Most Innovative Product Award.

Daiichi Sankyo has been pursuing specific emission reduction targets for both production sites and research and development centres since 2008. For example, the entire energy requirement of the German plant in Pfaffenhofen for the annual production of 2 billion tablets is generated by a local biomass power plant.

Enhertu®: the most innovative product for oncologists in the field of advanced breast carcinoma

In Pharma Trend, Daiichi Sankyo has long been one of the most sustainable and innovative pharmaceutical companies in Germany. The research-based company receives the award “The Most Innovative Product” from oncologists for Enhertu® 2022 for the treatment of breast cancer. The active substance trastuzumab-deruxtecan (T-DXd ) is an antibody-drug conjugate with a targeted effect on HER2-positive breast cancer cells. Cancer specialists voted for Enhertu® mainly because of its innovative mode of action (76%) combined with improved efficacy (64%) and novelty to the market (52%).

Awards for Daiichi Sankyo for innovation

Daiichi Sankyo first received the 2022 Award for Innovation and Sustainability for Enhertu®.

  • Enhertu® (2022)
About the award ceremony

The awards were announced on 13 September 2022 at the Deutsches Museum in Munich. The keynote speech was given by the patron of the event, the Bavarian Minister of Health Klaus Holetschek, Bavarian State Ministry of Health and Care. The festive awards ceremony was hosted by TV presenter Tamara Sedmak (Sat 1, n-tv, N24).

Pharma Trend - The market research on innovation and sustainability

The basis for the ranking and the awards is the Pharma Trend benchmark study, which has been conducted annually in the Rx category among physicians in Germany since 2000 and since 2018 also in the OTC and Orphan Drugs categories, and since 2019 also in the Specialty Care category on behalf of the PharmaBarometer magazine (https://pharmabarometer.de/pharmabarometer/). In 2021, the study was expanded to include the categories “Diagnostics” and “Digital Health Applications”. With the expansion of Pharma Trend, companies in pharmaceuticals and medical technology are assessed on innovation and sustainability via their most important stakeholders – doctors, pharmacists and patients. This year, Pharma Trend was conducted online with 700 physicians, including allergists, general practitioners, dermatologists, gynaecologists, oncologists/haematologists, paediatricians and urologists, as well as 100 pharmacists and 600 patients.

Further information on Pharma Trend and the report volumes at https://pharma-trend.com/en/

Related posts:

  1. Bencard ranks 6th in Pharma Trend Ranking 2022
  2. Astellas ranks 10th in Pharma Trend Ranking 2022
  3. Incyte ranks 9th in Pharma Trend Ranking 2022
  4. Lilly ranks 9th in the Pharma Trend Ranking 2022
Posted in: Allgemein Tagged: Ranking

Patronage

Melanie Huml, Minister of Bavarian State Ministry of Health and Care

Pharma Trend Image and Innovation Award

The survey of innovation and sustainability in pharmaceutical companies.

  • Deutsch
  • English

In the News

  • Pharmaceuticals and Biotechnology Manufacturing and Supply Agreement Trends Analysis Report and Directory 2020-2025 – ResearchAndMarkets.com July 5, 2025
  • Cardiovascular Collaboration and Licensing Agreements Analysis Report 2025 with Directory of 589 Deals Signed Since 2015 – Company A-Z, Headline Value, Therapeutic Area, Technology Type – ResearchAndMarkets.com July 4, 2025
  • Janitorial Services Market Insights and Forecasts, 2021-2024 & 2025-2031 | Rise of Eco-Friendly Solutions and Advanced Technologies Propel Growth – ResearchAndMarkets.com July 4, 2025
  • Pregnancy Detection Kits Market Trends, Opportunity, and Forecast, 2020-2024 & 2025-2030 | Digital Transformation Drives Innovations, Overcoming Accessibility and Awareness in Underdeveloped Markets – ResearchAndMarkets.com July 4, 2025
  • WELL Health Announces Voting Results for Election of Directors July 4, 2025

Partners




Bio M ist Partner der Goldenen Tablette



Media Partnerships



Esanum ist Medienpartner der Goldenen Tablette







Sponsors & Partners:


ashfield
lucky7even is sponsor of Pharma Trend
Harris Interactive is partner of Pharma Trend
PharmaBarometer
Dorothea Küsters Life Science Communications
EQS-Group is sponsor of Pharma Trend
Esanum
MCC Logo
JJ Sustainability is sponsor of Pharma Trend
Healthcare Marketing Logo weiß
Bio-M
Gesdat Logo
tiny web is sponsor of Pharma Trend

Copyright © 2023 Eurecon Verlag GmbH

Imprint   |   Privacy Statement